The novel neoclerodane diterpene Salvinorin A is the most potent naturally occurring hallucinogen. It has been reported to be the first subtype selective opioid ligand. In a screening against an array of receptors, Salvinorin A inhibited only kappa-opioid receptors (KORs). The activation of KORs has been documented to induce a wide range of behavioral effects, including sedation and perceptual distortions. Given its high selectivity, Salvinorin A could be used to investigate the precise role of KORs in the modulation of human perception. This has promoted interest in the development of a concise chemical synthesis of Salvinorin A. The synthetic scheme proposed for Salvinorin A should construct the molecule in an efficient manner. The key step is an intramolecular double Michael reaction, which assembles the tricyclic core and five of the seven stereocenters. A chiral bis(oxazolinyl) copper(II)-catalyzed vinylogous aldol condensation and a chirl auxiliary-mediated aldol reaction will be used to install the remaining two stereogenic centers. A late stage intermediate is readily amenable toward the preparation of analogues for use in a structure-activity relationship study.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
5F32DA019748-03
Application #
7291505
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Babecki, Beth
Project Start
2005-09-26
Project End
2008-07-01
Budget Start
2007-09-26
Budget End
2008-07-01
Support Year
3
Fiscal Year
2007
Total Cost
$38,811
Indirect Cost
Name
Harvard University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
082359691
City
Cambridge
State
MA
Country
United States
Zip Code
02138